Please login to the form below

Not currently logged in
Email:
Password:

Srdjan Stankovic joins Acadia Pharmaceuticals

He moves to the San Diego biopharma from Alkermes

San Diego biopharmaceutical company Acadia Pharmaceuticals has appointed Srdjan (Serge) Stankovic as executive vice president, head of research and development.

He joins the firm from Alkermes, where he most recently served as senior vice president of clinical development and medical affairs from 2013 to 2015.

Prior to this he worked at Teva as senior vice president and head of global clinical development following that company's acquisition of Cephalon, where he was senior vice president, worldwide clinical research. 

Stankovic has also held executive positions in research and development at Forest Laboratories, Neurogen, Johnson and Johnson and UCB.

Steve Davis, Acadia's president and chief executive officer, said: “Serge has a track record of transforming promising research into important medicines that address unmet needs of patients.

"We look forward to his contributions as we advance Nuplazid through NDA review for Parkinson's disease psychosis, prepare for the planned commercialisation of Nuplazid in the US  and continue our efforts to explore the full potential of Nuplazid to treat patients suffering from additional CNS disorders.” 

Nuplazid (pimavanserin), Acadia's lead candidate, has been submitted to the US FDA for a licence to treat Parkinson's disease psychosis, a condition that currently has no approved treatment.

Stankovic said: “There is a strong need for continued innovation in the treatment of CNS disorders such as Parkinson's disease, Alzheimer's disease, and schizophrenia. Acadia is at the forefront in developing groundbreaking medicines to treat debilitating symptoms associated with these diseases.

"I look forward to leading the team in advancing the promising development programmes with Nuplazid."

11th January 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics